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THINKING ABOUT THE FUTURE
Think of every belief you have about health care, every
assumption (e.g., “I get sick, I go to the doctor . . . ”). Now,
turn each one over, pull it inside out, imagine how it could
be made false (e.g., “What if I don’t wait until I am sick?
What if the doctor comes to me? What if the help that
comes is not a doctor? How could that be? . . . ”).
This is the future of healthcare. The combination of
demographic shifts and cost pressures and a flood of new
technologies—both biological and digital—promise that
the new century and the coming generation will see the
creative destruction and rebirth of what we know today as
health care.
In no field is this more true than in cardiovascular
medicine, situated as it is at the nexus of the most advanced
technologies, the most expensive techniques, the conditions
most sensitive to changing lifestyles and demographics, and
the deepest scientific understandings.
In the coming years, and even during just the next decade,
cardiovascular medicine will undergo radical changes in
technique and understanding, even as health care undergoes
radical changes in structure, payment systems, and informa-
tion flow. Cardiovascular medicine will never again be what
it was.
Yet we can make no specific predictions; crystal balls do
not work. The future is unknown. Whatever the future of
cardiovascular medicine is, it will not be exactly the way we
paint it here. There are too many unknowns and even
unknown unknowns.
So, how can we think about the future at all? We can
create scenarios, reasonably plausible depictions based on a
mixture of current breakthroughs, promising current re-
search, and thoughtful extrapolations from current research.
We can offer more detailed pictures of how events might
unfold if current research produces results. Finally, to
support these future images, we can offer an overview of
where we are now: today’s most promising areas of research
and their possible future developments.
SCENARIOS
2009. At 60, you actually feel better than you did at 50,
because of exercise, plenty of sleep, moderate habits, and the
fact that you quit smoking at 50. But you have not been to
the doctor much lately, so when you ask your physician to
authorize a physical examination, you get a bit of a surprise.
You expected more probing, a detailed talk with the doctor,
and maybe some tests of blood or urine. Instead, the
technician pricks your finger, takes a single drop of blood
with a hand-held device the size of a computer mouse, and
says, “Thank you. That will be all.” Two minutes later, as
you are still putting the bandage on your finger, the
technician pops back into the room, hands you a printed
slip, and says, “You’re going to have to come talk to the
life-stylist. You have no symptoms yet, but your genome
says you’re heading for heart disease.”
2024. At 75, you still feel better than you did at 50, again
because of exercise, plenty of sleep, and moderate habits as
well as breakthroughs in antiglycosylation therapy. The man
sitting next to you on the rocket plane to Mumbai seems
quite normal, until the conversation you are having with
him takes an odd twist, and you swap medical histories. You
learn that he has a pig heart, and his arteries are swarming
with “smart dust” that constantly reports on his condition,
directly over the Internet, to his physician’s database. These
facts strike you as strange, a coincidence worthy of com-
ment, because you have a pig heart, too. In fact, the man
tells you, it is not strange at all anymore.
2049. At 100, you still feel better than you did at 50, still
because of exercise, plenty of sleep, and moderate habits as
well as breakthroughs in antiglycosylation therapy, whole-
sale organ replacement in your eighties, and the nanolabs in
your blood stream that manufacture pharmaceuticals as
needed and constantly top up your telomerase, the enzyme
that makes your cells immortal. With all of this help, your
cardiovascular system ticks like a grandfather clock, and you
never give it a second thought. You have given up on
retirement. Who could afford it anyway, with so many Baby
Boomers hanging on past 100?
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IMAGES OF THE NEAR FUTURE: 1999–2009
Genomic revolution. It is 2009. During the past 10 years,
the unraveling of the human genome has turned out to be
the Rosetta Stone of the human body. The work of the
Human Genome Project, together with the work of such
private firms as Celera and Human Genome Sciences—to
parse the genome at the turn of the century—was a true
turning point in medical history and in the history of
cardiovascular medicine.
Every disease—in fact, every state of the human body—is
the result of some genes expressing proteins and some genes
suppressing other genes or modifying proteins expressed by
other genes. The picture will never be simple, but eventually
our understanding of the human genome will tell us what
actually is happening in our cells. In this way, genomics (the
study of the genome), proteomics (the study of the full
complement of human proteins), bioinformatics (the tech-
niques of gathering and processing all of this knowledge),
and systems biology (the study of how all of these processes
work as a complex adaptive system) are fundamentally
different from all medical studies preceding them. Other
studies dealt with effects; whereas these studies are the first
to give us a direct look at the actual biochemical pathways of
human development, health, and disease.
In cardiovascular medicine, the results of these genomic
studies have been realized in two main paths: predictive
diagnostics and pharmaceuticals.
PREDICTIVE POWER OF GENOMICS. Genomics and bioin-
formatics have given cardiovascular specialists a powerful
new tool—the ability to predict heart disease even decades
before symptoms appear (1).
By the end of the decade, inexpensive hand-held biosen-
sors had been introduced and were capable of detecting a
wide range of diseases within minutes by analyzing a drop of
blood, urine, saliva, or breath or even by bouncing micro-
radar off of the skin (2). The core of this hand-held device
is the “lab on a chip” (a miniature chemical laboratory as
small as 3 mm square) combined with a micro-array chip
that fluoresces in patterns that advertise the presence of
particular proteins or gene expressions and an analysis chip
that compares the pattern of genes or proteins expressed to
known patterns associated with particular disease states
(3,4). Some chips search for tell-tale single-nucleotide
polymorphisms (SNPs), which are patterns of tiny gene
mutations that have been shown to be predictive of heart
disease. Pharmacogenomic chips search for SNPs that tell
how the patient will respond to particular drugs.
Pharmaceutical firms, as recently as the early 1990s
starved for candidate compounds to test, have been wading
through tens of thousands of possibilities, using the growing
areas of genomics, proteomics, bioinformatics, and auto-
mated compound searches. The resulting flood of powerful
new pharmaceuticals has begun to render many surgeries
unnecessary:
c The use of cholesterol-controlling statins steadily in-
creased throughout the decade as knowledge of their
benefits spread among generalists, prices fell, and generic
brands appeared;
c Angiogenesis drugs, such as vascular endothelial growth
factor (VEGF), obviated the need for much bypass
surgery by growing new arteries on damaged hearts;
c Anti-angiogenesis drugs (e.g., endostatin), locally im-
planted in arterial plaque, inhibit its growth;
c Myogenesis drugs rebuild damaged heart muscles;
c Antiglycosylation therapies prevent the cross-linking that
weakens aging heart muscle;
c New vaccines raise high-density lipoprotein (HDL) levels
to help stave off heart disease;
c New genomic therapies repair damage after a myocardial
infarction and prevent the mass apoptosis that commonly
follows;
c A nicotine vaccine allows smokers who wish to quit
smoking to rid themselves of the physical craving for
cigarettes; and
c New antibiotics are used prophylactically to prevent
chlamydia and other infections, which cardiovascular
specialists continue to investigate as a cause of cardiovas-
cular disease.
Nutriceuticals. These new surgical and pharmaceutical
therapies have combined with the rapid rise in popularity of
nutriceuticals, or so-called functional foods, that actively
contribute to heart health. Margarines and cooking oils
made with plant sterols and stanols, which “taste fat” but
actually lower low-density lipoprotein (LDL) cholesterol
and raise HDL cholesterol, have replaced butter, other
cooking oils, and other fats in many packaged foods and
fast-food offerings. Major packagers of common foods, from
breakfast cereals to frozen foods, market “heart-healthy”
lines high in plant sterols and stanols and flavonoid anti-
oxidants (5–11).
Surgery. In the decade since 1999, surgical techniques and
devices have continued their rapid improvements. Stents
have proliferated into a wider range of sizes and are capable
of working in smaller arteries. New materials have greatly
reduced the incidence of restenosis. Catheters have likewise
become smaller and more maneuverable, affording surgeons
a wider range of insertion points and a plethora of capabil-
ities, from the now-traditional angioplasty to the decade-old
electrical killing of fibrillating cells, laser techniques to
encourage the growth of new blood vessels, and the direct
placement of new angiogenesis drugs.
Tools for performing surgery on beating hearts have
proliferated from the few available in 1999 to dozens. In
fact, most heart operations are conducted without stopping
the heart.
Minimally invasive surgery and intervention techniques
are now used for all routine heart surgeries, even intracardiac
(inside the heart) surgery. Cracking the chest is reserved for
rare and difficult cases or for full organ replacement.
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Robotics. Surgical robots, first introduced in the late
1990s, have become common as well. All major hospitals
use them for their greater precision and speed, lower cost,
and shorter recovery times. Whereas the first robots either
operated cameras and lights or were direct extensions of the
surgeon’s hands, robots are now more often actually per-
forming surgery—cutting, clamping, and suturing at the
surgeon’s direction, guided by voice commands (“Robot,
suture”), by the movements of a mouse on a screen (high-
light the area, click on “suture”), or by programming based
on pre-operation three-dimensional images.
Imaging. Imaging has continued the rapid improvement of
the previous decades. Magnetic resonance (MR) images
taken via catheter are now commonplace. Since the late
1990s, image-processing techniques have combined data
from a wide variety of sources (including angiography,
computerized tomography [CT], MR, electron-beam
[EBCT], echocardiogram, and MR echocardiogram) to
produce three-dimensional, scalable images (12,13). Ten
years later, advances in processing power and software allow
surgeons not only to see three-dimensional images of the
patient’s actual heart but also to tour the heart in “virtual
reality” and in real time, even as they operate, without the
necessity of placing a lens inside the body.
Replacement hearts. Electromechanical replacement
hearts have become common. It is no longer unusual to see
older people at the beach wearing battery packs at their belts
and taking them off for a dip in the surf (14). The cost
associated with these replacements is less than half of the
cost of a human heart transplant (15). Less obvious are the
thousands of people walking around with swine hearts,
which are now beginning to be used in situations that
previously would have called for reparative surgery (16–18).
Equally important are the thousands of people with replace-
ment coronary arteries constructed from bovine and swine
collagen (19).
Patient data. Connecting heart patients with practitioners
for daily check-ins through software, the Internet, and
small, easy-to-use home monitors has become standard
practice, widely praised for keeping patients stable and
healthy while keeping costs down. For some higher-risk
patients, daily monitoring is not enough. They conduct
their daily business while wearing “smart clothing”—
undershirts, bras, or belts that monitor basic vital signs, such
as pulse. The moment that any dangerous pattern emerges
(e.g., a racing pulse, fibrillation, or wide variations in heart
rate), a nurse at the patient’s disease management provider
is alerted through the Internet or the cellular phone system
and initiates a response (20).
Electronic medical records built around an industry-wide
information standard have become the norm. In fact, most
people carry their own records with them. Some carry the
information in “smart cards” with embedded data chips.
Others carry credit-card-size CD-ROMs that can be read
by any computer, or a card imprinted with a Web address
and personal identification number that gives online access
to their records (21).
Standardization of diagnoses and clinical practice. At
the same time that these new techniques and treatments
have revolutionized cardiovascular medicine, clinical prac-
tice has become more standardized across the U.S. and even
around the globe. The massive efforts of the American
College of Cardiology (ACC)-National Cardiovascular
Data Registry™ (NCDR™) and other organizations in
collecting, analyzing, and disseminating information have
resulted in a general set of consensus guidelines. These
guidelines evolve constantly with new in-the-lab medical
research results and with new in-the-field information about
outcomes (what actually happens when real people with real
heart disease and real complications receive particular ther-
apies). This widespread reporting system allows the spe-
cialty as a whole to stay continuously aware of unfolding
best practices, and this concentrated data study dramatically
narrows the range of unnecessary variation, thereby leading
to higher standards of care and, in many cases, lower costs.
Diagnosis also has become far more standardized. The
College has led a major drive to identify genomic and
proteomic patterns that display a wide variety of types of
heart disease or predict it years in advance.
THE NEXT GENERATION: 2009–2024
It is 2024.
In the face of an older population, the number of cardiac
surgeries has actually fallen as the Baby Boom generation
has aged. The maturing genomic revolution has led to an
array of drugs that together have brought much of heart
disease under pharmaceutical control.
Heart exchange is the single most common type of
open-chest surgery. In fact, except for unusual circum-
stances, it is the only type. Swine hearts are now common in
older people. After a furious ethical debate, the use of
organs from pigs has surged from the few thousand of the
first decade of the century to hundreds of thousands per
year, supplanting virtually all types of surgery meant to
repair a failing heart, including bypass grafting, resection-
ing, and valve replacements (22).
The mechanical alternative has improved greatly in a
generation. Not only has it become far more reliable, but
also it no longer needs to have its batteries recharged.
Instead, it is driven, just like a native heart, by the body’s
own metabolism.
Neo-organs—replacement organs grown in the labora-
tory from the patient’s own cells—have finally become a
clinical reality. In a generation of slowly expanding experi-
ments, researchers have moved from growing thin sheets of
heart muscle capable of sustaining a heartbeat to growing
entire hearts, complete with vessels for carrying the blood
supply, shaped over armatures that then dissolve (23).
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The first nanomachines have now entered cardiovascular
medicine, repairing and clearing arteries as well as delivering
pharmaceuticals to precisely targeted sites (24–28). Nano-
tech has also produced “smart materials,” used for arterial
walls, connective tissue, and even replacement muscle tissue,
that mimic natural human tissue in adapting to their site
and responding to hormonal and nervous signals (29).
Nanotechnology has also produced sensing devices the
size of bacteria, covered with a protein skin that mimics
human blood cells. Injected into the body, these “smart-
dust” sensors circulate harmlessly in the bloodstream, re-
cording body chemistry, hemodynamic flow and pressure,
and whatever else they had been programmed to look for.
They report the information to outside monitors by con-
structing characteristic information signatures easily de-
tected by the inexpensive monitors in the shape of full-
length mirrors, scanners, or the next generation of “smart
clothing” (30).
Biotechnology has produced harmless cigarettes laced
with nonaddictive nicotine substitutes, its tars and multiple
other substances subtly altered to render them harmless
while still satisfying to the smoker.
“Just-in-time” knowledge. Over this quarter century, the
ACC-NCDR™ has evolved into the single most powerful
and centralized tool for managing and combating heart
disease. It catalogues outcomes of millions of cases across
the U.S. and around the world. It steadily turns those
outcome studies into practice guidelines and disseminates
them to primary practitioners and specialists alike.
At the same time, the ACC-NCDR™ has participated in
identifying the genomic and proteomic fingerprints of every
variety of cardiovascular disease, allowing nearly instant and
nearly certain diagnosis.
As the baby boomers age, the demand for cardiovascular
knowledge and care rapidly increases, and many boomer
cardiologists retire. Encouraging more medical students to
enter the specialty is important and useful, but insufficient,
so the ACC has moved aggressively to use technical means
to overcome the problem.
By 2015, the ACC-NCDR™ has built genomic finger-
prints, more traditional diagnostic criteria, and its practice
guidelines and scientific notes into diagnostic-assistance
software that is constantly updated over the Internet. By
answering a series of questions and entering test results, a
primary practitioner or nurse can diagnose a patient’s heart
problem as if the most skilled specialist were standing at his
or her elbow.
One version of the software watches the patterns of
information that physicians or nurses enter into a patient’s
electronic record. When patterns emerge that suggest a
different diagnosis or therapy, the software comes to the fore
to ask questions and offer “just-in-time” information tai-
lored to the particular patient and the clinical situation.
Spreading accurate, useful cardiovascular clinical knowl-
edge as widely as possible through every technique that
works has become a primary goal of the College’s NCDR™
and the ACC in general.
Altogether, the field of cardiovascular medicine is more
important than ever, as rapid advances in organ replace-
ment, pharmaceuticals, telomerase therapy, and antiglyco-
sylation therapy have combined to produce extraordinarily
youthful aging baby boomers. The boomers see opening up
to them the possibility of living much longer than any
previous generation, and they will pursue any therapy at any
cost—paid for by them, by their insurance, or by society—
that will lengthen their lives.
OUR CHILDREN AND GRANDCHILDREN: 2024–2049
It is 2049.
Heart replacement surgeries, which peaked about 2024,
are now almost nonexistent. Today, few hearts, whether
native human hearts or the old xenotransplants, become
damaged enough to need surgical repair or replacement.
The tremendous and continuing exploration of the
genomic roots of heart disease have brought a continuous
and rapid improvement in prediction, diagnosis, and phar-
maceutical therapies.
By the 2020s, most people were being scanned annually
(and those at high risk, more often) by technologists armed
with hand-held genomic scanners. In the early years, the
information led to recommendations for lifestyle changes,
such as shifts in diet, exercise patterns, smoking, or other
consumption habits.
By the 2030s, however, the hand-held scanners were no
longer needed. Injectable “smart dust” had advanced to the
point that it could continually report, and deliver as part of
the daily routine, genomic shifts and changes in language
that the consumer could understand. At the same time, the
recommendations changed from diet and lifestyle to phar-
maceuticals.
Pharmaceuticals had become so successful at preventing
cardiovascular damage—and repairing any damage that did
occur—that diet and lifestyle changes were no longer
necessary. People could eat whatever they wanted, smoke,
and avoid exercise while their cardiovascular systems
pumped away like antique mechanical Swiss watches—as
long as they took the pharmaceuticals the mirror prescribed.
By the 2040s, even the pharmaceuticals were rapidly
becoming outmoded. Nanotechnology had gone beyond
“smart dust” to universal bio-assemblers. Floating in the
bloodstream, these minuscule factories could act on
genomic information derived on their travels through the
bloodstream, combined with information and reprogram-
ming continually and automatically downloaded from the
Internet as medical science arrived at new understandings.
The bio-assemblers could put together the needed pharma-
ceuticals on demand from locally available chemicals in the
bloodstream.
As the ACC approaches its centenary celebration in
2049, it finds itself engaged in a far-reaching and furious
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debate within its ranks. The question is “Should the ACC
reconstitute itself in some new shape for its second century?”
Some radicals even suggest that the College should be
abolished, that the specialty of cardiovascular medicine itself
should go the way of polio specialists. They argue that the
understanding of the underlying genomic structures has
advanced so far that there is very little study, and few
techniques or therapies, that are truly specific to the heart.
Cardiac surgery has all but disappeared. Almost all heart
therapy is now preventive and is carried out either through
pharmaceuticals (now considered old fashioned) or through
information exchange to the universal bio-assemblers. By
now, in the mid-twenty-first century, there are still many
types of medical specialties; but the trend of the era is to
build specialties not around organs or systems but around
ways of looking at the overall system, such as genomics,
proteomics, medical nanomics, systems biology, and bioin-
formatics.
But the voices of the mainstream argue that the College
still has a mission that is central to the practice of medicine.
The heart, with its attendant systems, remains the central
driver of the body, with their own special problems. In fact,
during the half-century from 1999 to 2049, the ACC has
rapidly evolved, linking these new sources of knowledge
directly to the actual field practice of cardiovascular medi-
cine. It is this rapid, practical response that has succeeded in
taming what once was the greatest killer of all.
REALITY CHECK
All discussion of the future is, of course, some species of
speculation. No one can truly know the future. These
speculations, however, are based on current research efforts
and the possibilities they bring to light extrapolated into the
future.
Most of the near-term possibilities are based on the
reasonable supposition that discoveries and techniques that
are new today will be refined during the next 10 years. They
will come into common use to the extent that they are found
to be useful, safe, and affordable. Most of the possibilities
from 10 to 25 years in the future are extrapolations from
current research and are necessarily more speculative.
Beyond 25 years from now, we are making reasonable
guesses. In most cases, results that depend on engineering
(e.g., robotics, imaging) come more quickly and more
certainly than results that directly involve biology (e.g.,
neo-organs) or results that depend on popular awareness
(e.g., switching to cholesterol-controlling margarines). Bi-
ology and sociology are far more complex than engineering.
In all cases, of course, the speculations spring from where
we are today.
Genomics. A rough draft of the complete human genome
should be ready by mid-2000, and a final draft within two
years (31). Human Genome Sciences, Inc., claims to have
already mapped nearly all of the genes that actually express
in the human body (32). A group of 11 major pharmaceu-
tical companies has founded the SNP Consortium with a
$45 million budget and the goal of mapping an estimated
300,000 SNPs.
The task of identifying all of the proteins in the human
body is also proceeding apace, complicated by the fact that
estimates of their numbers range from roughly 100,000 (the
number of human genes) to 100 million. Much of the
enormous task of finding the patterns of genes, proteins,
and SNPs that signal disease or genetic predisposition to
disease remains to be done—and the task is highly complex.
However, it is not necessary to wait for all of the genomic
information to be in place before it becomes clinically useful.
Already, at the beginning of 2000, one biotechnology firm
began offering a home DNA kit that would allow consumers
to test their blood for SNPs that herald adverse drug
reactions (33). According to the Biotechnology Industry
Organization, by mid-1999 more than 80 pharmaceuticals
derived from this information had already been approved by
the Food and Drug Administration (FDA), more than 350
were in various stages of FDA testing, and more than
10,000 compounds have been identified as targets for testing
as possible drugs over the next five years (34).
The examples of genomic drugs mentioned previously are
in various stages of development:
c Cholesterol-controlling statins are available but underuti-
lized (35–38);
c Several types of angiogenesis VEGF are in human clinical
trials; early results have been mixed, but the idea still
seems sound (39,40);
c Endostatin has recently been shown to be effective in
forestalling the growth of arterial plaque (41,42);
c Myogenesis drugs, antiglycosylation therapies, and
genomic therapies to repair damage after myocardial
infarction are still in early research stages (43–46);
c An HDL-raising vaccine has been successful in animal
trials (47,48);
c A nicotine vaccine has been successfully tested in labora-
tory rats, with human trials planned within two years (49);
c Whether prophylactic antibiotics might help prevent
cardiovascular disease is under active investigation
(50,51).
Surgery. Stents are in common use today. Interventionist
and minimally invasive techniques are becoming more
common (52).
Beating-heart surgery was introduced in 1998 (53–56).
Robotic heart surgery, pioneered by U.S. firms, entered the
commercial market in Europe in 1998, and human clinical
trials were launched in the U.S. in 1999. Early experience
has proven that robots, with their more-than-human dex-
terity, stability, and precision, can execute through mini-
mally invasive ports some operations for which human
surgeons would have to open the chest (e.g., Atrial-Septal
Defect [ASD] closure) (57,58). It is not yet clear whether
robotic surgery will ever become faster, more cost effective,
or better for the patient than traditional surgery.
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The single largest question about the future of cardiac
surgery is how soon pharmaceutical advances will actually
cause a drop in the volume of procedures. Clearly, if even
some of the current genomic lines of research produce useful
results, then those pharmaceuticals will obviate the need for
many of today’s surgical and interventionist procedures.
Successful VEGF drugs in particular could replace coronary
artery bypass grafts (CABGs), the single most common
major operation in the nation. The population is aging, yet
the bulk of the baby boom generation will not reach the
prime age for heart disease until after the year 2015. This
question is of major importance for planners designing new
surgical units and for medical schools educating cardiac
surgeons. This area is a prime candidate for computer
modeling that would test the sensitivity of various assump-
tions.
Imaging. Experimental techniques can combine data from
different sources to produce three-dimensional, scalable
images from any point of view with any level of transparency
for different types of tissue (59–61). The extrapolation of
these images into real-time, three-dimensional, noninter-
ventionist “fly-throughs” of the human body largely depends
on further large advances in computing capacity. Although
Moore’s Law (which postulates an 18-month doubling
period in computer power) is experiencing some fundamen-
tal physical problems, a range of investigations, ranging
from single-molecule logic gates to quantum computing,
allows us to imagine that Moore’s Law will continue to
operate, and computing power will continue to increase at a
rapid pace (62–66).
Replacement hearts. Electromechanical replacement hearts
are ready to enter human clinical trials in this calendar year
(67). The idea that such hearts may someday be able to beat
without an outside battery is purely speculative. Clearly, the
human body has such power available, as it powers the native
heart, but so far no artificial muscle that derives energy from
native metabolic processes has been developed.
Swine hearts are similarly ready for human trials, accord-
ing to the chief proponent of the technique, Dr. Jeffrey Platt
of the Xenotransplant Institute at the Mayo Clinic, in
Rochester, Minnesota (68). The concern that swine hearts
might introduce porcine retroviruses into humans has
proven ill-founded (69).
Research into building neo-organs has shown that heart
muscle cells can be cultured outside of the body, grown on
a matrix into a thin, continuous sheet, and made to beat as
a unit (70). Other researchers have constructed arteries of
bovine and porcine collagen coated with heparin (71). How
long these experiments will take to produce full lab-grown
hearts is impossible to tell, but the possibility seems on the
one hand to be quite real and on the other hand to be at least
a generation in the future.
Heart replacement may well become the dominant form of
heart surgery, but looking ahead from 2000, it is not clear what
the specific replacement will be—a mechanical heart, a swine
heart xenograft, or a heart grown from the patient’s own
fibroblasts. A generation ahead, these operations may ulti-
mately be superceded by directly inducing fibroblasts to grow
muscle, valve tissue, or arteries in situ to replace damaged
tissue.
Nanotech. Nanotechnology is still in its infancy—part
theory, part basic design, and part experiment. Theoreti-
cians have produced plausible designs of gears, pumps, and
other basic mechanical structures built from altered hydro-
carbon molecules. Experimenters have built molecular-scale
propellers and rachets. At least one experimenter claims to
have built basic shapes (e.g., cubes, octohedrons) as well as
a crude logic gate by altering DNA molecules (72). Al-
though the field seems promising, no one has yet built a
working nanomachine of any kind. We are at least a
generation away from useful nanoproducts.
Patient data. A number of firms have pioneered the use of
the Internet, in combination with blood pressure cuffs and
other devices, to maintain constant contact between chronic
heart failure patients and their health providers. Initial tests
show significant drops in emergency room visits, hospital-
izations, and cost as well as significant increases in func-
tional ability (73–76).
Smart cards, wallet-size CD-ROM cards, and Web sites
that store patient medical records are already a reality.
Unfortunately, industry-wide technical standards for elec-
tronic medical records have not yet been adopted, and a
majority of health care systems still use paper records. The
blocks to changing these practices are not technical but
political, cultural, and economic.
Standardization of diagnoses and clinical practice. The
ACC’s NCDR™ is one of the College’s most important
recent initiatives. Together with the ACC/American Heart
Association Task Force on Practice Guidelines and the
ACC expert consensus documents, the NCDR™ is in-
tended to become a major force to spread best-practice
knowledge throughout the specialty.
“Just-in-time” knowledge. The pieces of a “just-in-time”
knowledge system already exist. These include rapidly grow-
ing databases of diagnostic and practice guidelines; “diag-
nostic assistance” software; experiments with software that
can recognize patterns in diagnosis, treatment, or pharma-
ceuticals and offer new knowledge; Internet-ready personal
digital assistants (PDAs) designed for medical use; and the
World Wide Web to connect together the PDAs and the
databases (77–82). Developing these pieces into a widely
accepted, seamless system that would be a major enhance-
ment of clinical practice is no longer a technical problem but
an economic and cultural one.
Life extension. Will all of these medical and technical
breakthroughs actually extend people’s lives? The answer is
far from obvious, because it is a general-systems question,
and our knowledge is largely about subsystems. Even curing
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heart disease entirely would only add a few years to the lives
of bodies that are prey to many other diseases as well as to
the multiple systemic degradations and failures that are part
of the aging process. Yet the kind of deep understanding of
human biochemistry that would lead to a complete cure of
heart disease could not exist in a vacuum: such deep under-
standing would undoubtedly lead to cures, preventatives, or
powerful therapies for many other diseases and conditions.
Furthermore, some studies, such as those on telomerase and
glycosylation, seem to offer insight into the aging process itself.
It is on this general-systems question that our conclusions
are clearly the most speculative. Yet, we believe that it is quite
possible that the next 50 years will see the introduction of
therapies that will allow people to live significantly longer lives.
SUMMARY
The fiftieth anniversary of the ACC and the end of the
twentieth century are arbitrary points in time, yet they seem
to coincide with a true watershed. The last 50 years have
brought a rush of new techniques and understandings that
have, for the first time, given cardiovascular specialists real
tools to prevent and fight cardiovascular disease. Only now,
for the first time, has science begun to understand exactly
what happens when plaque forms in an artery, when heart
muscle fibers cross-link and weaken, when an atrial chamber
fibrillates, and when heart muscle cells die en masse after a
heart attack. We are beginning to track down the actual
chemical, mechanical, and electrical pathways by which the
heart is damaged or dies. When we can interfere with those
pathways and stop the chain of events, we will have defeated
heart disease.
Imagination is rapid, but progress is often both uncertain
and slow because of the many constraints of cost, regulation,
and time needed to test and evaluate new developments. Yet
we can now foresee a future in which medical science
might actually defeat cardiovascular disease the way it has
defeated polio, smallpox, and other serious scourges of
the past.
Technological Advances and the Next
50 Years of Cardiology: Ethics and Privacy
Joe Flower, MA, Leonard S. Dreifus, MD, MACC,* Alfred A. Bove´, MD, PhD, FACC,†
William S. Weintraub, MD, FACC‡
Technology is ineluctably human. It could be said that our
ability to produce technology is what defines us as humans.
It is who we are.
Technology is driven by our desires. So, it is not surpris-
ing that every new development prompts debates about
ethics, morality, and philosophy. These debates can be
boiled down to the questions, “Who are we, as humans?”
and “What do we really want?”
These questions became especially vivid during the cri-
tiques and discussions around early versions of this report.
For instance, some new developments raise the possibility of
extending the human life span beyond its current limits.
That possibility is not at all a consensus goal among physicians
or cardiovascular specialists. Some consider it morally suspect.
The moral, ethical, legal, and social issues raised by these
new technologies include the following:
GENOMICS
Privacy. If it becomes possible by mapping the SNPs in
your genome to determine not only which diseases and
syndromes you have now but also which ones you are likely
to have in the future, to whom should this information be
made available? Your insurors? Your employer? Your pro-
spective employers? Your school? Your spouse? Your dating
partners? Your friends and neighbors? Government agen-
cies?
Wherever we draw the bright line of privacy, how should
we enforce it? What should we do about the black market in
genomic information that will inevitably develop?
Do we have a right to not know our own future? If you
could know your own health future decades in advance,
would you want to? Will we be able to refuse the knowledge,
or will it be forced on us?
Cost. Already, one of the greatest problems that physicians
report in getting patients to comply with their drug regi-
mens is that the patients simply cannot afford the drugs.
Many older people, especially those who are living on fixed
incomes and facing multiple health problems, have to
choose between eating and taking a full course of their heart
medicine. The new drugs derived from genomic informa-
tion may greatly exacerbate this problem. Some will be
inexpensive. Many will be expensive but cheaper than the
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surgeries and other treatments that they replace. Others will
be expensive by any measure, reflecting their enormous
research costs. These costs could create an ever-widening
gap between those who can afford powerful new medicines
and those who cannot.
REPLACEMENT HEARTS
Swine hearts. Online discussions with a variety of author-
ities in what is kosher under the dietary laws of Judaism and
under the laws of Islam show little concern that replacing a
human heart with a swine heart would be religiously
forbidden. Some do not consider surgery to be equivalent to
eating. Most cite traditions that suspend such laws when
necessary to save a life.
Neo-organs. To grow a heart muscle, you start with a
donated human egg cell, substitute genetic material from a
cell taken from the person for whom you are growing the
heart muscle, and grow the resulting embryo in a laboratory
dish to the 100-cell blastocyst stage. Then, you strip off
the outer layer of cells, disaggregate the inner cell mass,
and grow it into a colony of embryonic stem cells. Finally,
you stimulate them chemically to differentiate as myo-
cytes, heart muscle cells.
Until you strip off the outer layer of the blastocyst, the
embryo is a human clone. Implanted in a uterus, it could grow
into a full human being. To some, this means that it is a full
human being and should not be used for any purpose, no
matter how noble. To others, it is only a potential human being
and does not become a human unless it is implanted in a
uterus. Much the same process has occurred without
comment for decades in fertility clinics doing in-vitro
fertilizations (a number of embryos are created; when one
is successfully implanted, the others are destroyed). Yet
the idea of using embryonic stem cells has already created
controversy and is currently under congressional ban in
any laboratory receiving federal funds. Some experiment-
ers believe, however, that neo-organs can be grown from
more mature cells—fibroblasts—thus avoiding this par-
ticular problem.
PATIENT DATA
Turning medical records into digital data makes copying
them far easier and arouses privacy concerns, much the same
as the creation of genomic data. The main protection for
smart cards is that they require special readers. The main
protection for CD-ROM cards and cards with personal
identification numbers for Web sites is the patient’s physical
possession of them.
LIFE EXTENSION
The idea of extending people’s lives beyond what seems to
be their natural limit is not supported by any ethical
consensus. Many physicians consider their goal to be curing
disease, easing pain and disability, and avoiding early
death—not extending life.
If methods of extending life prove to be feasible, then it is
likely that they will be considered medically unnecessary, like
cosmetic surgery, and so will not be covered. This means that
only the financially well-off will live longer—a situation that is
sure to provoke a great deal of ethical debate.
These ethical concerns are likely to slow research in certain
areas, delay the adoption of some techniques for general use,
and help mold the eventual shape of the technologies that
come into use over the next decades. Technology is not some
neutral force set apart from people; it is an expression of human
desires and world views through scientific means.
Technological Advances and the
Next 50 Years of Cardiology: Glossary
Joe Flower, MA, Leonard S. Dreifus, MD, MACC,* Alfred A. Bove´, MD, PhD, FACC,†
William S. Weintraub, MD, FACC‡
Because this article is more likely than most articles in the
Journal of the American College of Cardiology to be read by
members of the media and other noncardiologists, we
provide definitions of a few of the technical terms used:
Angiogenesis: growth of new arteries; in cardiology, angio-
genesis typically refers to the use of new drugs, such as vascular
endothelial growth factor (VEGF) to promote the growth of
new cardiac arteries that supply the heart muscles with blood.
Angioplasty: various techniques to re-open arteries that have
been narrowed or closed by arterial plaque.
Apoptosis: cell self-destruction.
Catheters: long, wirelike instruments typically inserted
into large arteries to do work in the heart or the arteries.
1089JACC Vol. 35, No. 4, 2000 Flower et al.
March 15, 2000:1082–91 Technological Advances and the Next 50 Years of Cardiology
Fibrillation: the random and ineffective firing of any of
the four vessels that comprise the heart.
Genomic: relating to the genome, the entire pattern of
genes in the body; a genetic study would look at patterns
passed down through generations in the genes; a genomic
study, by contrast, would focus on patterns of genes
expressing, or being suppressed, in any given state of
health or disease.
Glycosylation: a process by which glucose causes pro-
teins to cross-link into longer and less flexible chains and
networks; glycosylation is implicated in many of the
common signs of aging, such as wrinkles, glaucoma, the
plaques formed in the brains of Alzheimer’s disease
sufferers, and many of the complications of adult-onset
diabetes mellitus.
High-density lipoprotein (HDL): “good” cholesterol,
which actually helps prevent cardiovascular problems.
Interventionist techniques: techniques that work
through long, thin catheters inserted through tiny inci-
sions into arteries or veins, rather than by inserting larger
instruments through incisions in the body.
Low-density lipoprotein (LDL): “bad” cholesterol,
which leads to the formation of plaque in arteries.
Minimally invasive surgery: surgery conducted through
small ports cut into the body; the surgeons use long tools
with tiny video lenses, lights, or surgical instruments at
the end.
Myogenesis: growth of new muscle; in cardiology, myo-
genesis typically refers to the attempt to create drugs that
will promote the growth of new heart muscles to supple-
ment muscles that have been damaged by myocardial
infarction or other heart disease.
Nanotechnology: the art and craft of creating molecular-
scale machines.
Proteomic: relating to the “proteome,” the entire pattern
of proteins in use in the body; while a genomic study
would focus on patterns of genes expressing, or being
suppressed, in any given state of health or disease, a
proteomic study would look at the patterns of proteins
that those genes are building.
Restenosis: reclosing of arteries after angioplasty.
Stents: mesh tubes placed in arteries to keep them open.
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